• Optimizing RCC and MTC Assays with Cabozantinib (XL184, BMS-

  2026-06-23

  This article addresses practical laboratory challenges in kinase inhibitor assays and demonstrates how Cabozantinib (XL184, BMS-907351) (SKU A2977) from APExBIO ensures reproducible, data-driven results. By analyzing real-world scenarios in renal cell carcinoma and medullary thyroid cancer models, we highlight protocol optimization, data interpretation, and vendor selection strategies for reliable experimental outcomes.

• EZ Cap Cy5 Firefly Luciferase mRNA: Dual Imaging and Trackin

  2026-06-23

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) enables real-time, dual-modality imaging and mRNA delivery tracking. Dive into the latest science, unique workflow insights, and practical assay guidance beyond standard protocols.

• BMS-777607: c-Met Inhibitor Transforming Cancer & Stem Cell

  2026-06-22

  BMS-777607 stands out as a selective c-Met inhibitor enabling breakthroughs in both cancer metastasis modeling and advanced stem cell differentiation protocols. This guide translates the latest research and expert workflows into actionable steps, troubleshooting strategies, and cross-domain insights for reproducible results.

• Hypoxia-Induced lncRNA SHIELD Drives GPX4 Translation in HCC

  2026-06-22

  This study uncovers how the hypoxia-responsive lncRNA SHIELD promotes GPX4 translation, protecting hepatocellular carcinoma (HCC) cells from ferroptosis. By delineating the SHIELD–GRSF1–GPX4 axis, the findings offer new directions for overcoming therapeutic resistance in HCC.

• Cx43/NF-κB Pathway in AngII-Induced Macrophage Polarization

  2026-06-21

  This article analyzes recent findings on how Angiotensin II drives macrophage polarization toward the M1 phenotype via the connexin 43/NF-κB signaling pathway. The study provides mechanistic insights relevant to cardiovascular inflammation and highlights the functional consequences of targeting Cx43 hemichannels in immune modulation.

• Applied Use-Cases of Cholecystokinin Octapeptide Ammonium in

  2026-06-20

  Cholecystokinin octapeptide ammonium (CCK-8 ammonium) unlocks precise modulation of neurobehavioral, immunological, and cardiometabolic pathways, offering unique advantages for both in vitro and in vivo studies. This article bridges the latest mechanistic evidence with practical guidance, highlighting protocol optimization and troubleshooting for reproducible results.

• Docetaxel: Precision Oncology Insights Beyond Microtubule In

  2026-06-19

  Explore how Docetaxel advances cancer chemotherapy research by integrating microtubule inhibition with cellular heterogeneity analysis. This article offers unique, evidence-backed protocol guidance and reveals new opportunities for precision oncology.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-06-19

  Anlotinib hydrochloride streamlines angiogenesis and tumor research with potent, selective inhibition across VEGFR2, PDGFRβ, and FGFR1. Discover actionable workflows, troubleshooting tactics, and comparative data that position this APExBIO multi-target tyrosine kinase inhibitor as a gold standard for advanced cell-based assays.

• Dimethyloxalylglycine (DMOG): Technical Use and Protocol Gui

  2026-06-18

  Dimethyloxalylglycine (DMOG) enables controlled stabilization of hypoxia-inducible factor (HIF) by inhibiting prolyl-4-hydroxylase enzymes, making it indispensable for in vitro and in vivo modeling of hypoxia signaling and immune modulation. It should be used strictly for laboratory research—diagnostic or therapeutic applications are not supported.

• Translational Strategies Using Anlotinib Hydrochloride in An

  2026-06-18

  This article explores the mechanistic underpinnings, experimental validation, and translational trajectory of Anlotinib hydrochloride as a next-generation multi-target tyrosine kinase inhibitor for anti-angiogenic cancer research. Integrating recent preclinical evidence and practical workflow guidance, it provides strategic recommendations for researchers seeking to leverage this compound’s selectivity, safety, and translational promise.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Re

  2026-06-17

  Xiao et al. reveal that 25-hydroxycholesterol (25HC), produced via CH25H upregulation in tumor-associated macrophages (TAMs), accumulates in lysosomes and activates AMPKα, leading to STAT6-dependent immunosuppressive programming. This mechanistic insight positions CH25H as an immunometabolic checkpoint, with implications for re-educating TAMs and improving anti-tumor responses, particularly in combination with immune checkpoint blockade.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib via Ferroptosi

  2026-06-17

  This study demonstrates that silencing TRIB3 enhances the sensitivity of clear cell renal cell carcinoma (ccRCC) to Sunitinib by promoting ferroptosis through the SLC7A11/GPX4 pathway. The findings offer a mechanistic basis for overcoming Sunitinib resistance in ccRCC and suggest new research strategies for targeting ferroptotic cell death in resistant tumors.

• Pulsed Plasma Degradation of Sulfamonomethoxine: Findings an

  2026-06-16

  This study demonstrates the effective degradation of sulfamonomethoxine (SMM) in aqueous solution using pulsed plasma discharge, revealing both the removal kinetics and the formation of transient by-products. The research highlights the environmental implications of plasma-generated hydrogen peroxide, emphasizing the need for further optimization to minimize ecotoxicity in water treatment applications.

• ATRX-Deficient Glioma Cells: Sensitivity to RTK Inhibition

  2026-06-16

  The referenced study identifies that ATRX-deficient high-grade glioma cells display increased vulnerability to multi-targeted receptor tyrosine kinase (RTK) and PDGFR inhibitors. This mechanistic insight supports the strategic use of RTK inhibitors in ATRX-mutant glioma models, with implications for both preclinical research and clinical trial design.

• Berberine Suppresses SASP Inflammation via RXRα/PPARγ/NEDD4

  2026-06-15

  This study reveals that berberine mitigates senescence-associated secretory phenotype (SASP)–driven inflammation in atherosclerosis by activating the RXRα/PPARγ/NEDD4 pathway in macrophage-derived foam cells. The research provides mechanistic clarity on how targeting this axis may offer new strategies for modulating chronic vascular inflammation and age-related cardiovascular disease.

14763 records 1/985 page Next 12345 下5页 Last page